Department of Psychiatry and Psychotherapy, Medical Faculty, University of Cologne, Cologne, Germany.
German Linguistics, University of Koblenz, Koblenz, Germany.
Alzheimers Dement. 2024 Nov;20(11):7635-7656. doi: 10.1002/alz.14226. Epub 2024 Oct 1.
Understanding the impact of biomarker-based dementia risk estimation in people with mild cognitive impairment (MCI) and their care partners is critical for patient care.
MCI patients and study partners were counseled on Alzheimer's disease (AD) biomarker and dementia risk was disclosed. Data on mood, quality of life (QoL), and satisfaction with life (SwL) were obtained 1 week and 3 months after disclosure.
Seventy-five dyads were enrolled, and two-thirds of the patients opted for biomarker testing. None of the participants experienced clinically relevant depression or anxiety after disclosure. All dyads reported moderate to high QoL and SwL throughout the study. Patients reported more subthreshold depressive symptoms 1 week and lower QoL and SwL 3 months after disclosure. In patients, depression (odds ratio [OR]: 0.76) and anxiety (OR: 0.81) were significant predictors for the decision against biomarker testing.
No major psychological harm is to be expected in MCI patients and care partners after dementia risk disclosure.
This study is registered in the German clinical trials register (Deutsches Register Klinischer Studien, DRKS): http://www.drks.de/DRKS00011155, DRKS registration number: DRKS00011155, date of registration: 18.08.2017.
Patients with mild cognitive impairment (MCI) and study partners were counseled on Alzheimer's disease (AD) biomarker-based dementia risk estimation. About two-thirds of patients opted for biomarker testing and received their dementia risk based on their AD biomarker status. Patients who decided in favor or against CSF biomarker testing differed in psychological features. We did not observe major psychological harm after the dementia risk disclosure. Coping strategies were associated with better subsequent mood and well-being in all participants.
了解生物标志物为基础的痴呆风险评估在轻度认知障碍（MCI）患者及其护理伙伴中的影响对于患者护理至关重要。
对 MCI 患者及其研究伙伴进行了关于阿尔茨海默病（AD）生物标志物和痴呆风险的咨询，并在披露后 1 周和 3 个月时获得了情绪、生活质量（QoL）和生活满意度（SwL）的数据。
共纳入 75 对患者，其中三分之二的患者选择进行生物标志物检测。披露后，没有参与者出现临床相关的抑郁或焦虑。所有的参与者在整个研究过程中报告了中度到高度的 QoL 和 SwL。患者在披露后 1 周报告了更多的亚临床抑郁症状，而在 3 个月时报告了更低的 QoL 和 SwL。在患者中，抑郁（优势比 [OR]：0.76）和焦虑（OR：0.81）是对生物标志物检测做出反对决定的显著预测因素。
在 MCI 患者及其护理伙伴中，痴呆风险披露后预计不会出现重大心理伤害。
本研究在德国临床试验注册处（Deutsches Register Klinischer Studien，DRKS）注册：http://www.drks.de/DRKS00011155，DRKS 注册号：DRKS00011155，注册日期：2017 年 8 月 18 日。
对轻度认知障碍（MCI）患者及其研究伙伴进行了关于基于阿尔茨海默病（AD）生物标志物的痴呆风险评估的咨询。大约三分之二的患者选择进行生物标志物检测，并根据其 AD 生物标志物状况获得痴呆风险。赞成或反对 CSF 生物标志物检测的患者在心理特征上有所不同。我们在痴呆风险披露后没有观察到重大的心理伤害。在所有参与者中，应对策略与更好的后续情绪和幸福感相关。
